Mark Hopman - 29 Jan 2025 Form 3 Insider Report for Beta Bionics, Inc. (BBNX)

Role
Chief Commercial Officer
Signature
/s/ Stephen Feider , Attorney-in-Fact
Issuer symbol
BBNX
Transactions as of
29 Jan 2025
Net transactions value
$0
Form type
3
Filing time
29 Jan 2025, 21:43:39 UTC
Next filing
03 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BBNX Employee Stock Option (right to buy) 29 Jan 2025 Class B Common Stock 83,242 $5.10 Direct F1, F2
holding BBNX Employee Stock Option (right to buy) 29 Jan 2025 Class B Common Stock 37,229 $5.10 Direct F2, F3
holding BBNX Employee Stock Option (right to buy) 29 Jan 2025 Class B Common Stock 17,765 $8.51 Direct F2, F4
holding BBNX Employee Stock Option (right to buy) 29 Jan 2025 Class B Common Stock 39,424 $10.74 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to this option shall vest one year after March 20, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
F2 In accordance with the Issuer's Amended and Restated Certificate of Incorporation, the Issuer's outstanding shares of Class B Common Stock will convert into an equal number of shares of Common Stock immediately prior to the closing of the initial public offering.
F3 The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
F4 The shares subject to this option shall vest in 48 equal monthly installments measured from January 1, 2024.
F5 The shares subject to this option shall vest in 48 equal monthly installments measured from September 10, 2024.